Trial Profile

Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temsirolimus (Primary)
Indications CNS cancer; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms TemPCNSL

Most Recent Events

14 Mar 2016 Status changed from recruiting to completed, as per results published in the Journal of Clinical Oncology.
14 Mar 2016 Results published in the Journal of Clinical Oncology
10 Apr 2013 Planned end date changed from 1 Mar 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com